Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Basket Study of Disitamab Vedotin in HER2-expressing Solid Tumors (Japan)
jRCT2031240536Phase 2Suspended
- Sponsor
- Seagen Inc.
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), Ovarian Epithelial Adenocarcinoma and 3 more, sponsored by Seagen Inc. Primary endpoint: Confirmed Objective Response Rate (ORR). Started Jan 2025; status: suspended.
02
Drugs
disitamab vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2031240536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240536.